Results 41 to 50 of about 2,353 (181)

Characteristics of pncA mutations in multidrug-resistant tuberculosis in Taiwan

BMC Infectious Diseases, 2011
Background Pyrazinamide (PZA) is an important first-line drug in multidrug-resistant tuberculosis (MDRTB) treatment. However, the unreliable results obtained from traditional susceptibility testing limits its usefulness in clinical settings.
Lee Yu-Chin, Yu Kwok-Woon, Huang Shiang-Fen, Chiu Yu-Chi, Feng Jia-Yih, Su Wei-Juin   +5 more
doaj   +1 more source

pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea

BMC Infectious Diseases, 2001
Background Pyrazinamide (PZA) is among the first-line drugs for the treatment of tuberculosis. In vitro, it kills semidormant mycobacteria only at low pH.
Kim Cheol Min, Son Han Chul, Lee Min Ki, Chang Chulhun Ludgerus, Lee Jung Yoo, Park Soon Kew, Jang Hyun Jung, Park Hee Kyung, Jeong Seok Hoon   +8 more
doaj   +1 more source

Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China

BMC Infectious Diseases, 2021
Background Detection of pyrazinamide (PZA) resistance in Mycobacterium tuberculosis (TB) patients is critical, especially in dealing with multidrug-resistant Mycobacterium tuberculosis (MDR-TB) case.
Yang Che, Dingyi Bo, Xiang Lin, Tong Chen, Tianfeng He, Yi Lin   +5 more
doaj   +1 more source

Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico

Infection, Genetics and Evolution, 2013
Numerous studies have linked mutations in the pncA gene with resistance to pyrazinamide (Z) in Mycobacterium tuberculosis. However, variations in these mutations are specific to the country of origin of the isolate. The aim of this study was to characterize changes in pncA gene sequence in isolates of M. tuberculosis with resistance to Z, from patients
Betzaida, Cuevas-Córdoba, Sheila Oyuki, Xochihua-González, Aremy, Cuellar, Javier, Fuentes-Domínguez, Roberto, Zenteno-Cuevas   +4 more
openaire   +2 more sources

Spoligotyping with pncA sequencing strategy conferring the transmission of multidrug-resistant tuberculosis in Egypt

International Journal of Mycobacteriology, 2019
Background: This study explored the genetic diversity of Mycobacterium tuberculosis isolates in Egypt by spoligotyping in combination with pncA gene sequencing, spoNC. Methods: First, isolates were selected from 400 isolates positive for M.
Suzan Ismail, Khaled Al Amry, Galal Aggor, Hoida El Naggar, Salah Selim   +4 more
doaj   +1 more source

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China

BMC Infectious Diseases, 2020
Background Pyrazinamide still may be a useful drug for treatment of rifampin-resistant (RR-TB) or multidrug-resistant tuberculosis (MDR-TB) in China while awaiting scale up of new drugs and regimens including bedaquiline and linezolid.
Hui Xia, Susan van den Hof, Frank Cobelens, Yang Zhou, Bing Zhao, Shengfen Wang, Yanlin Zhao   +6 more
doaj   +1 more source

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. [PDF]

PLoS ONE, 2017
Besides inclusion in 1st line regimens against tuberculosis (TB), pyrazinamide (PZA) is used in 2nd line anti-TB regimens, including in the short regimen for multidrug-resistant TB (MDR-TB) patients. Guidelines and expert opinions are contradictory about
Jean Claude Semuto Ngabonziza, Awa Ba Diallo, Elisa Tagliani, Bassirou Diarra, Abalo Essosimna Kadanga, Antieme Combo George Togo, Aliou Thiam, Willem Bram de Rijk, Riccardo Alagna, Sabine Houeto, Fatoumata Ba, Anoumou Yaotsè Dagnra, Emil Ivan, Dissou Affolabi, Valérie Schwoebel, Arnaud Trebucq, Bouke Catherine de Jong, Leen Rigouts, Géraldine Daneau, “Union short MDR-TB regimen study group”   +19 more
doaj   +1 more source

Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan

BMC Infectious Diseases, 2019
Background Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB).
Muhammad Tahir khan, Shaukat Iqbal Malik, Sajid Ali, Nayyer Masood, Tariq Nadeem, Anwar Sheed Khan, Muhammad Tanvir Afzal   +6 more
doaj   +1 more source

Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China

BMC Infectious Diseases, 2017
Background Pyrazinamide (PZA) plays a unique role in the treatment for multidrug-resistant tuberculosis (MDR-TB) in both first- and second-line regimens.
Yu Pang, Damian Zhu, Huiwen Zheng, Jing Shen, Yan Hu, Jie Liu, Yanlin Zhao   +6 more
doaj   +1 more source

Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China.

PLoS Neglected Tropical Diseases, 2021
BackgroundMultidrug-resistant tuberculosis (MDR-TB) poses a serious challenge to TB control. It is of great value to search for drug resistance mutation sites and explore the roles that they play in the diagnosis and prognosis of MDR-TB.MethodsWe ...
Qiao Liu, Dandan Yang, Beibei Qiu, Leonardo Martinez, Ye Ji, Huan Song, Zhongqi Li, Jianming Wang   +7 more
doaj   +1 more source